102 related articles for article (PubMed ID: 29563326)
1. Extending a Systems Model of the APP Pathway: Separation of
van Maanen EMT; van Steeg TJ; Ahsman MJ; Michener MS; Savage MJ; Kennedy ME; Kleijn HJ; Stone J; Danhof M
J Pharmacol Exp Ther; 2018 Jun; 365(3):507-518. PubMed ID: 29563326
[TBL] [Abstract][Full Text] [Related]
2. Systems Pharmacology Analysis of the Amyloid Cascade after β-Secretase Inhibition Enables the Identification of an Aβ42 Oligomer Pool.
van Maanen EM; van Steeg TJ; Michener MS; Savage MJ; Kennedy ME; Kleijn HJ; Stone JA; Danhof M
J Pharmacol Exp Ther; 2016 Apr; 357(1):205-16. PubMed ID: 26826190
[TBL] [Abstract][Full Text] [Related]
3. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
4. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
[TBL] [Abstract][Full Text] [Related]
5. CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition.
Dobrowolska JA; Michener MS; Wu G; Patterson BW; Chott R; Ovod V; Pyatkivskyy Y; Wildsmith KR; Kasten T; Mathers P; Dancho M; Lennox C; Smith BE; Gilberto D; McLoughlin D; Holder DJ; Stamford AW; Yarasheski KE; Kennedy ME; Savage MJ; Bateman RJ
J Neurosci; 2014 Jun; 34(24):8336-46. PubMed ID: 24920637
[TBL] [Abstract][Full Text] [Related]
6. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
8. Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages.
Devi L; Ohno M
Neuroscience; 2015 Oct; 307():128-37. PubMed ID: 26314636
[TBL] [Abstract][Full Text] [Related]
9. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
10. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
11. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound.
Cook JJ; Wildsmith KR; Gilberto DB; Holahan MA; Kinney GG; Mathers PD; Michener MS; Price EA; Shearman MS; Simon AJ; Wang JX; Wu G; Yarasheski KE; Bateman RJ
J Neurosci; 2010 May; 30(19):6743-50. PubMed ID: 20463236
[TBL] [Abstract][Full Text] [Related]
12. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
13. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processing.
Liu X; Wong H; Scearce-Levie K; Watts RJ; Coraggio M; Shin YG; Peng K; Wildsmith KR; Atwal JK; Mango J; Schauer SP; Regal K; Hunt KW; Thomas AA; Siu M; Lyssikatos J; Deshmukh G; Hop CE
Drug Metab Dispos; 2013 Jul; 41(7):1319-28. PubMed ID: 23584887
[TBL] [Abstract][Full Text] [Related]
15. Beta-secretase/BACE1 promotes APP endocytosis and processing in the endosomes and on cell membrane.
Wang M; Jing T; Wang X; Yao D
Neurosci Lett; 2018 Oct; 685():63-67. PubMed ID: 30120949
[TBL] [Abstract][Full Text] [Related]
16. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
17. Chronic Cerebral Hypoperfusion Promotes Amyloid-Beta Pathogenesis via Activating β/γ-Secretases.
Cai Z; Liu Z; Xiao M; Wang C; Tian F
Neurochem Res; 2017 Dec; 42(12):3446-3455. PubMed ID: 28836062
[TBL] [Abstract][Full Text] [Related]
18. Thymoquinone-rich fraction nanoemulsion (TQRFNE) decreases Aβ40 and Aβ42 levels by modulating APP processing, up-regulating IDE and LRP1, and down-regulating BACE1 and RAGE in response to high fat/cholesterol diet-induced rats.
Ismail N; Ismail M; Azmi NH; Bakar MFA; Yida Z; Abdullah MA; Basri H
Biomed Pharmacother; 2017 Nov; 95():780-788. PubMed ID: 28892789
[TBL] [Abstract][Full Text] [Related]
19. The role of low-density receptor-related protein 1 (LRP1) as a competitive substrate of the amyloid precursor protein (APP) for BACE1.
von Einem B; Schwanzar D; Rehn F; Beyer AS; Weber P; Wagner M; Schneckenburger H; von Arnim CA
Exp Neurol; 2010 Sep; 225(1):85-93. PubMed ID: 20685197
[TBL] [Abstract][Full Text] [Related]
20. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.
Nishitomi K; Sakaguchi G; Horikoshi Y; Gray AJ; Maeda M; Hirata-Fukae C; Becker AG; Hosono M; Sakaguchi I; Minami SS; Nakajima Y; Li HF; Takeyama C; Kihara T; Ota A; Wong PC; Aisen PS; Kato A; Kinoshita N; Matsuoka Y
J Neurochem; 2006 Dec; 99(6):1555-63. PubMed ID: 17083447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
